Ceapro

Ceapro Inc. is a Canadian biotechnology company specializing in the development and commercialization of active ingredients derived from oats and other renewable plant resources. The company serves clients in the healthcare and cosmetic industries, leveraging its expertise in natural product chemistry, microbiology, biochemistry, immunology, and process engineering. Ceapro's core products include Avenanthramides and Beta Glucan, which are isolated from oat products to naturally enhance cosmetic and personal care products. The company also utilizes its proprietary PGX technology, a novel spray drying technique for processing water-soluble biopolymers, to supply ingredients to well-known personal care and cosmetic industries worldwide.

Ceapro operates in the cosmeceuticals, nutraceuticals, and pharmaceuticals markets, focusing on both in and out licensing opportunities. The company's business model includes the sale of active ingredients, licensing of its proprietary technologies, and offering specialized contract manufacturing services. Ceapro generates revenue through direct sales, licensing agreements, and strategic partnerships.

In 2017, Ceapro acquired JuventeDC, a product line that includes oat beta glucan and avenanthramides, which have shown significant improvement in subjects suffering from eczema and psoriasis. This acquisition aligns with Ceapro's strategy to get closer to the customer and expand its product offerings.

Keywords: biotechnology, oat-derived, active ingredients, healthcare, cosmetics, PGX technology, cosmeceuticals, nutraceuticals, pharmaceuticals, contract manufacturing.